MX2024004443A - Promotores de estereocilina y usos de estos. - Google Patents

Promotores de estereocilina y usos de estos.

Info

Publication number
MX2024004443A
MX2024004443A MX2024004443A MX2024004443A MX2024004443A MX 2024004443 A MX2024004443 A MX 2024004443A MX 2024004443 A MX2024004443 A MX 2024004443A MX 2024004443 A MX2024004443 A MX 2024004443A MX 2024004443 A MX2024004443 A MX 2024004443A
Authority
MX
Mexico
Prior art keywords
promoters
strc
stereocilin
expression product
hair cells
Prior art date
Application number
MX2024004443A
Other languages
English (en)
Spanish (es)
Inventor
Leah Sabin
Samuelson Meghan Drummond
Joseph Burns
Tyler Gibson
Martin Schwander
Lars Becker
Original Assignee
Decibel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decibel Therapeutics Inc filed Critical Decibel Therapeutics Inc
Publication of MX2024004443A publication Critical patent/MX2024004443A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024004443A 2021-10-12 2022-10-12 Promotores de estereocilina y usos de estos. MX2024004443A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163254930P 2021-10-12 2021-10-12
US202263307484P 2022-02-07 2022-02-07
US202263338605P 2022-05-05 2022-05-05
PCT/US2022/046444 WO2023064388A2 (en) 2021-10-12 2022-10-12 Stereocilin promoters and uses thereof

Publications (1)

Publication Number Publication Date
MX2024004443A true MX2024004443A (es) 2024-07-01

Family

ID=85988783

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004443A MX2024004443A (es) 2021-10-12 2022-10-12 Promotores de estereocilina y usos de estos.

Country Status (9)

Country Link
US (1) US20240401079A1 (cg-RX-API-DMAC10.html)
EP (1) EP4416294A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024538076A (cg-RX-API-DMAC10.html)
KR (1) KR20240109294A (cg-RX-API-DMAC10.html)
AU (1) AU2022364798A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235268A1 (cg-RX-API-DMAC10.html)
IL (1) IL312056A (cg-RX-API-DMAC10.html)
MX (1) MX2024004443A (cg-RX-API-DMAC10.html)
WO (1) WO2023064388A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021530227A (ja) 2018-07-13 2021-11-11 アコーオス インコーポレイテッド 非症候性感音性聴力喪失の治療方法
CN116836975A (zh) * 2022-03-25 2023-10-03 上海玮美基因科技有限责任公司 一种耳蜗和/或前庭细胞特异性启动子及其应用
WO2024250774A1 (zh) * 2023-06-07 2024-12-12 苏州星奥拓维生物技术有限公司 耳蜗外毛细胞特异性启动子及其应用
CN116925239B (zh) * 2023-07-17 2024-10-18 苏州星奥拓维生物技术有限公司 双载体系统表达Otof基因的组合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161031A1 (en) * 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
JP2021530227A (ja) * 2018-07-13 2021-11-11 アコーオス インコーポレイテッド 非症候性感音性聴力喪失の治療方法
US12534739B2 (en) * 2018-10-11 2026-01-27 Decibel Therapeutics, Inc. AAV1 vectors and uses thereof for treatment of otic indications
CA3219054A1 (en) * 2021-05-05 2022-11-10 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using stereocilin dual vector systems

Also Published As

Publication number Publication date
JP2024538076A (ja) 2024-10-18
AU2022364798A1 (en) 2024-05-02
EP4416294A4 (en) 2026-05-13
EP4416294A2 (en) 2024-08-21
WO2023064388A2 (en) 2023-04-20
IL312056A (en) 2024-06-01
KR20240109294A (ko) 2024-07-10
US20240401079A1 (en) 2024-12-05
WO2023064388A3 (en) 2023-08-24
CA3235268A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
WO2023064388A3 (en) Stereocilin promoters and uses thereof
EA202091995A1 (ru) Композиции и способы лечения не связанного с возрастом нарушения слуха у субъекта-человека
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2022014085A (es) Composiciones y metodos para tratar la perdida de audicion asociada a gjb2.
PH12018500477A1 (en) Recombinant vectors comprising 2a peptide
MX2022005236A (es) Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina.
EP4219724A3 (en) Compositions and methods for treating non-age-associated hearing impairment in a human subject
MX2022013005A (es) Arni variante.
SA519401494B1 (ar) مستقبلات مولد ضد كيمري لعلاج سرطان
MX2022010050A (es) Composiciones y metodos para tratar deficiencia auditiva no asociada con la edad en un sujeto humano.
MX2018015684A (es) Composiciones y metodos para el agotamiento de celulas cd117.
MX2023013053A (es) Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de estereocilina.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
MX2018005467A (es) Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas.
WO2019118518A3 (en) Inducible cell receptors for cell-based therapeutics
WO2018189661A3 (en) Methods and compounds for treating diabetes
MY192577A (en) Ophthalmic solution comprising epinastine
WO2019222314A8 (en) Raav vectors encoding of lysosomal beta-galactosidase (glb1) and cathepsin a
MY209530A (en) Methods and compositions for the treatment of hair loss
WO2018220489A3 (en) METHODS OF OBTAINING CELLS FROM HUMAN OMBILICAL POST-PARTUM CORDON ARTERIAL TISSUE
MX2024002069A (es) Anticuerpos anti-hla-g.
JOP20200253A1 (ar) تركيبات وطرق لعلاج الحثل البقعي
WO2019171174A3 (en) Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
PH12021550950A1 (en) Method for culturing cord blood-derived natural killer cells using transformed t cells